Navigation Links
BioMS Medical Announces First quarter 2009 results

Toronto Stock Exchange Symbol: MS

EDMONTON, May 11 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced financial and operational results for the first quarter, ended March 31, 2009.

"We remain on track to obtain the results from MAESTRO-01, the first of our two pivotal trials evaluating dirucotide in patients with secondary progressive multiple sclerosis, in the second half of 2009," said Kevin Giese, President and CEO of BioMS Medical. "We have demonstrated in previous trials that dirucotide has shown to be well tolerated and has the capacity to slow the progression of disease in certain genetically pre-disposed MS patients. If our pivotal trials confirm these results, we believe dirucotide could represent the first drug with blockbuster potential for the treatment of secondary progressive multiple sclerosis."

Currently, BioMS is conducting two pivotal clinical trials and one open-label follow-on trial of dirucotide for the treatment of secondary progressive MS (SPMS):

    -  MAESTRO-01: On January 22, 2007, BioMS announced that this pivotal
       phase III trial, being conducted in Canada and Western Europe, had
       completed full recruitment of 611 SPMS patients at 47 trial sites in
       ten countries. The primary clinical endpoint for MAESTRO-01 (and
       MAESTRO-03) is defined as a statistically and clinically significant
       increase in the time to progression of the disease as measured by the
       Expanded Disability Status Scale (EDSS), in patients with HLA-DR2
       and/or HLA-DR4 immune response genes.

       On April 21, 2009 the DSMB conducted a scheduled safety analysis and
       recommended that the trial continue to completion. To date, there have
       been ten positive safety reviews from the Data Safety Monitoring Board
       (DSMB) and this was the final scheduled review by 
SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. BioMS Medical to present at Alberta Economic Forum in Geneva
2. BioMS Medical to present at BioFinance 2009
3. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
5. BioMS Medical Announces 2008 Year End Results
6. BioMS Medical warrant extension
7. BioMS Medical to present at BIO CEO and Investor Conference
8. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
9. BioMS Medical recognized at Scrip Awards 2008
10. BioMS Medical Announces Third Quarter 2008 Results
11. BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference
Post Your Comments:
(Date:3/2/2015)... 02, 2015 Shimadzu Scientific Instruments will ... on LCMS and marijuana analysis at the Pittcon 2015 ... to 12 at the Ernest N. Morial Convention Center ... by booth 3121 to discuss laboratory challenges with Shimadzu’s ... proven products help save time, money and effort in ...
(Date:3/2/2015)... YORK and VANCOUVER, British Columbia ... Inc. ("InMed") (CSE: IN; OTCQB: IMLFF), a clinical ... cannabinoid based therapies, today announced that Craig ... company overview during a live webcast at ... ET LINK: > click the ...
(Date:3/2/2015)... 2, 2015 VG Life Sciences, Inc., ... autoimmune and infectious diseases, announced that the U.S. ... important new composition of matter patent covering methods ... of CLIP. U.S. Patent No. ... Life Sciences, VG1177, a synthetic peptide which has ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 Increasing its efforts ... Films launches its first three episodes of The GMO TRUTH ... Project this month, as it continues its mission to discover ... the project's first phase, to “uncover the truth about the ... media. , The GMO Truth Podcast is an expansion of ...
Breaking Biology Technology:Shimadzu Scientific Instruments Announces Product Launches, Presentations and Poster Sessions for Pittcon 2015 2Shimadzu Scientific Instruments Announces Product Launches, Presentations and Poster Sessions for Pittcon 2015 3InMed Pharmaceuticals to Present Investor Webcast March 5 2VG Life Sciences Granted Key Composition Of Matter Patent 2VG Life Sciences Granted Key Composition Of Matter Patent 3The Walk a Mile Project Launches “GMO Truth” Podcast 2
... Ahmed Fazil Madison, Wis. - The 2006 ... has launched its first identity theft product, and has ... and three million customers after two years. , ,This probably ... plans to reach positive cash flow, but consider the total ...
... of Fresno in California's San Joaquin Valley is one of ... from grapes to livestock, from almonds to dairy products, and ... San Joaquin Valley these days is biofuel. , ,Like many ... recent visit are happy that demand for ethanol and biodiesel ...
... appears that Wisconsin has failed in its bid to lure a ... a maker of neural stem cell kits for researchers, apparently has ... it was spun out of the University of Georgia . ... likely that the company will remain in Georgia, despite an incentive ...
Cached Biology Technology:Identity theft start up has fast-track growth plans 2Identity theft start up has fast-track growth plans 3Kind approach to leveraging biofuels 2Kind approach to leveraging biofuels 3Georgia stem cell company likely to stay put 2
(Date:2/18/2015)... , Feb. 18, 2015  Cepheid (NASDAQ: CPHD ... the following conferences, and invited investors to participate via webcast. ... Boston, MA Tuesday, March 3, 2015 at 11.20 ... Orlando, FL Wednesday, March 4, 2015 ... To access the live webcasts for these events, please visit ...
(Date:2/12/2015)... 2015   MedNet Solutions , a global ... management systems, has recently bolstered its ... iMedNet as the eClinical solution ... healthcare consultants.  Building on the Program,s existing benefits ... numerous co-marketing opportunities), MedNet,s new and improved program ...
(Date:2/11/2015)... February 11, 2015 ... "Access Control Market by Product (Cards and Readers, Biometrics, ... Defense, Government, Industrial, Healthcare, Education) and By Geography - Global ... MarketsandMarkets, the Access Control Market is expected ... at a CAGR of 10.6% between 2014 ...
Breaking Biology News(10 mins):Cepheid to Webcast Upcoming Financial Presentations 2MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4
... Most drug therapy interventions for people with autism have ... Now, University of Missouri researchers are examining the use ... pressure and control heart rate as well as to ... with autism difficulty with normal social skills, language ...
... release is available in German . , London. The ... 45 per cent more than previously thought. This is the conclusion ... heavy oxygen atoms in the carbon dioxide of the atmosphere driven ... dioxide were converted faster than expected during the El Nio years, ...
... drug that would treat most, if not all, autoimmune disorders, ... not be so hard to do thanks to a team ... the body to prevent unnecessary immune reactions. This molecule, pronounced ... overreacting when food passes through our bodies, and it may ...
Cached Biology News:Study finds promising drug treatment for improving language, social function in people with autism 2Productivity of land plants may be greater than previously thought 2Productivity of land plants may be greater than previously thought 3Scientists discover a 'master key' to unlock new treatments for autoimmune disorders 2
ABgene® supplies a 94kDa ultra-pure recombinant thermostable DNA polymerase obtained by high level expression of the Taq DNA polymerase gene in E. coli....
... samples may be carried out using this ... attention. System control and data processing is ... The elegant, powerful and very easy to ... 98 and 2000., The supplied automatic sample injector ...
Heavy-duty rim. Especially recommended as a titration flask. Corning5100. capacity 250 mL Special grade: student grade...
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (F1676) or contact customer s...
Biology Products: